SynthesisWorld journal of surgical oncology2025
The impact of androgen deprivation therapy and novel hormonal therapy on thyroid hormone levels in prostate cancer patients: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough androgen deprivation therapy (ADT) and novel hormonal therapy (NHT) have improved the prognosis of prostate cancer (PC), the effect of ADT/NHT on thyroid hormone (TH) levels is highly controversial. We performed a systematic review and meta-analysis of peer-reviewed studies to investigate the effects of ADT/NHT on TH levels in PC patients.
methodMedical literature databases such as PubMed, Web of Science and Metstr were systematically searched for all potentially related clinical studies from their inception to July 10, 2025. The quality of the studies included in the review was evaluated using RevMan version 5.3 for the meta-analysis.
resultsThe systematic review and meta-analysis were based on 413 cases selected from three publications. No significant difference in thyroid stimulating hormone (TSH) levels was observed between the ADT and control groups (MD 0.23 [95% CI -0.01-0.48]; p = 0.06, I
conclusionsFor the first time, we showed no significant difference in the TSH level between the two groups, which might indicate that the TSH level was not affected by ADT in PC patients. Notably, in European countries, patients with long-term ADT were more likely to have lower FT4 levels than non-ADT patients were, but interestingly, all FT4 levels were within their reference intervals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.